drugset / Trial / NCT06059846

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT06059846

Phase 3 Completed 1690 enrolled Spero Therapeutics GlaxoSmithKline · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (greater than or equal to (≥)18 years of age) with cUTI or AP.

Timeline

Start
2023-12-21
Primary completion
2025-01-27
Completion
2025-02-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imipenem-Cilastatin Unknown 300 mg Intravenous
Comparator Imipenem-Cilastatin Unknown 400 mg Intravenous
Comparator Imipenem-Cilastatin Unknown 500 mg Intravenous
Subject TBP-PI-HBr Unknown 300 mg Oral
Subject TBP-PI-HBr Unknown 600 mg Oral

Indications